SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
New data confirms that trastuzumab deruxtecan has an exciting destiny, but the antibody-drug conjugate’s impressive efficacy in late-stage breast cancer comes at a price.
Ash 2019 – Regeneron takes the bispecific baton and runs
Regeneron and Xencor add to the growing evidence backing bispecifics in certain lymphomas, a space that looks set to become fiercely competitive.
Ash 2019 – Merck gets Arqule ahead of data
Arqule’s investors have done pretty nicely out of today’s buyout by Merck & Co, but might be wondering whether they could have done better still.
Ash 2019 – for Car-T the bispecific antibody threat is real
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
Ash 2019 – former Celgene holders look anxiously at contingent value
Celgene CVR holders have been desperate to find out whether JCAR017 is approvable. Yesterday at Ash they got their answer... kind of.
Ash 2019 – Johnson & Johnson overshadows Bluebird’s registrational reveal
This year’s Ash features numerous duelling anti-BCMA therapies in multiple myeloma, and the first clinical data for JNJ-4528 impress.
Ash 2019 – Roche doesn’t disappoint with bispecific
The first in-depth look Roche’s anti-CD20 bispecific, mosunetuzumab, reveals some very encouraging response rates, even in patients who failed Car-T therapy.
Biogen teases with lupus ahead of aducanumab's big Alzheimer’s reveal
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
SITC – the morning after the night before
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.